Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals

被引:49
作者
Fissell, WH [1 ]
Dyke, DB [1 ]
Weitzel, WF [1 ]
Buffington, DA [1 ]
Westover, AJ [1 ]
MacKay, SM [1 ]
Gutierrez, JM [1 ]
Humes, HD [1 ]
机构
[1] VA Med Ctr, Dept Med, Ann Arbor, MI USA
关键词
renal failure; cytokines; bioartificial kidney; sepsis; endotoxin shock;
D O I
10.1159/000046986
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The mortality from sepsis complicated by renal failure remains extremely high despite the application of modern renal replacement therapy. This study investigated whether treatment with a bioartificial kidney consisting of a hemofilter in a continuous venovenous hemofiltration circuit (CVVH) with a cartridge containing renal proximal tubule cells, also called the Renal Tubule Assist Device (RAD), would alter the course of sepsis in an animal model. The RAD has been previously characterized in vitro and ex vivo and provides transport, metabolic and endocrine activity. Mongrel dogs (n = 10) underwent surgical nephrectomy and 48 h later were treated with CVVH and either a RAD containing cells (n = 5) or an identically prepared sham cartridge (n = 5). After 4 h of therapy, intravenous endotoxin 2 mg/kg was infused over 1 h to simulate gram-negative septic shock. Data on blood pressure, cardiac output and systemic markers of inflammation were collected. Mean peak levels of an anti-inflammatory cytokine, IL-10, were significantly higher in cell-treated animals (15.25 vs. 6.29 ng/ml; p = 0.037), and mean arterial pressures were higher in cell-treated versus sham-treated animals (p < 0.04). We have demonstrated that treatment of an animal model of endotoxin shock and renal failure with a bioartificial kidney has measurable effects on circulating mediators of inflammation and on hemodynamic stability of the challenged animal. Copyright (C) 2002 S. Karger AG, Basel.
引用
收藏
页码:55 / 60
页数:6
相关论文
共 38 条
[1]  
BENARD GR, 2001, NEW ENGL J MED, V344, P699
[2]   Sepsis: A new hypothesis for pathogenesis of the disease process [J].
Bone, RC ;
Grodzin, CJ ;
Balk, RA .
CHEST, 1997, 112 (01) :235-243
[3]   A CONTROLLED CLINICAL-TRIAL OF HIGH-DOSE METHYLPREDNISOLONE IN THE TREATMENT OF SEVERE SEPSIS AND SEPTIC SHOCK [J].
BONE, RC ;
FISHER, CJ ;
CLEMMER, TP ;
SLOTMAN, GJ ;
METZ, CA ;
BALK, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 1987, 317 (11) :653-658
[4]   Why sepsis trials fail [J].
Bone, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (07) :565-566
[6]   Immunologic dissonance: A continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS) [J].
Bone, RC .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (08) :680-687
[7]  
Breen D, 1998, KIDNEY INT, V53, pS25
[8]   PROGNOSTIC VALUES OF TUMOR-NECROSIS-FACTOR CACHECTIN, INTERLEUKIN-1, INTERFERON-ALPHA, AND INTERFERON-GAMMA IN THE SERUM OF PATIENTS WITH SEPTIC SHOCK [J].
CALANDRA, T ;
BAUMGARTNER, JD ;
GRAU, GE ;
WU, MM ;
LAMBERT, PH ;
SCHELLEKENS, J ;
VERHOEF, J ;
GLAUSER, MP .
JOURNAL OF INFECTIOUS DISEASES, 1990, 161 (05) :982-987
[9]   STRATEGIES FOR BLOCKING THE SYSTEMIC EFFECTS OF CYTOKINES IN THE SEPSIS SYNDROME [J].
CHRISTMAN, JW ;
HOLDEN, EP ;
BLACKWELL, TS .
CRITICAL CARE MEDICINE, 1995, 23 (05) :955-963
[10]   A comparison between the acute effects of nitric oxide synthase inhibition and fluid resuscitation on myocardial function and metabolism in entotoxemic dogs [J].
Cohen, RI ;
Huberfeld, S ;
Genovese, J ;
Steinberg, HN ;
Scharf, SM .
JOURNAL OF CRITICAL CARE, 1996, 11 (01) :27-36